The impact of prevention-effective PrEP use on HIV incidence: a mathematical modelling study.
Africa
HIV prevention
PrEP
adherence
cost-effectiveness
modelling
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
04
04
2022
accepted:
31
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
ppublish
Résumé
Models that project the impact and cost-effectiveness of HIV pre-exposure prophylaxis (PrEP) must specify how PrEP use aligns with HIV exposure. We hypothesized that varying PrEP use according to individual-level partnership dynamics rather than prioritization to population subgroups based on average risk will result in larger incidence reductions and greater efficiency. We used an individual-based network transmission model calibrated to HIV dynamics in Eswatini to simulate PrEP use among individuals ages 15-34 between 2022 and 2031 under two paradigms of PrEP delivery: "Risk Group" and "Partnership." In the "Risk Group" paradigm, we varied PrEP coverage by risk groups (low, medium and high) defined by average partnership frequency and concurrency. In the "Partnership" paradigm, all individuals are potentially eligible for PrEP, but we assumed use occurs only during partnerships and varied prioritization by partner HIV status (no prioritization to high prioritization with HIV-positive partners). We calculated person-time on PrEP and incidence relative to a no PrEP scenario and estimated efficiency as the person-years of PrEP needed to avert one additional infection (NNT). In the Risk Group paradigm, restricting PrEP to the high-risk group was the most efficient (NNT = 17), but the number of infections averted was limited by the small size of the high-risk group. Expanding PrEP use to all risk groups averted up to three times more infections but with lower efficiency (NNT = 202). PrEP use under the Partnership paradigm was 2-6 times more efficient (NNT = 33-102) than the Risk Group paradigm with all groups eligible for PrEP. A 33% reduction in incidence among 15- to 34-year-olds was achieved at 46% (95% CI: 39-52%) PrEP coverage in the Risk Group paradigm and 6% (95% CI: 5-7%) to 17% (95% CI: 14-20%) in the Partnership paradigm. Modelling PrEP use based on risk groups resulted in a sharp trade-off between PrEP efficiency and impact, whereas PrEP use predicated on partnerships resulted in much higher efficiency for widespread PrEP availability. Model estimates of PrEP impact and cost-effectiveness in generalized epidemics are strongly influenced by assumptions about how PrEP use aligns with individual-level HIV exposure heterogeneity.
Identifiants
pubmed: 36385504
doi: 10.1002/jia2.26034
pmc: PMC9670193
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26034Subventions
Organisme : NIMH NIH HHS
ID : F30 MH122300
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Lancet HIV. 2021 Aug;8(8):e495-e501
pubmed: 34126052
J Int AIDS Soc. 2021 Oct;24(10):e25827
pubmed: 34648678
Lancet HIV. 2020 Jan;7(1):e38-e48
pubmed: 31813837
J Int AIDS Soc. 2019 Sep;22(9):e25390
pubmed: 31538407
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219831011
pubmed: 30776954
J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):251-260
pubmed: 35147580
PLoS Med. 2013;10(3):e1001401
pubmed: 23554579
J Int AIDS Soc. 2022 Aug;25(8):e25958
pubmed: 35929343
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):423-429
pubmed: 33136739
AIDS Behav. 2021 Dec;25(12):3871-3882
pubmed: 33826022
Pathog Dis. 2018 Jul 1;76(5):
pubmed: 29986020
J Infect Dis. 2016 Dec 15;214(12):1800-1807
pubmed: 27418048
Cult Health Sex. 2021 Sep;23(9):1198-1214
pubmed: 32633617
Lancet HIV. 2020 Apr;7(4):e249-e261
pubmed: 32087152
J R Soc Interface. 2013 Aug 28;10(88):20130613
pubmed: 23985734
Clin Infect Dis. 2022 Sep 30;75(7):1224-1231
pubmed: 35100612
PLoS Med. 2021 Jan 11;18(1):e1003482
pubmed: 33428611
Lancet. 2010 Jun 12;375(9731):2092-8
pubmed: 20537376
PLoS One. 2018 Jun 14;13(6):e0198680
pubmed: 29902205
Lancet HIV. 2020 May;7(5):e348-e358
pubmed: 32061317
AIDS. 2019 Jul 1;33(8):1369-1378
pubmed: 30932954
PLoS Med. 2018 Feb 27;15(2):e1002512
pubmed: 29485985
PLoS Med. 2021 Jun 18;18(6):e1003670
pubmed: 34143779
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25296
pubmed: 31328443
J Infect Dis. 2021 Apr 23;223(8):1345-1355
pubmed: 31851759
AIDS Behav. 2021 Apr;25(4):1112-1119
pubmed: 33106996
Front Reprod Health. 2021 Aug 12;3:637869
pubmed: 36304002
Lancet HIV. 2022 Oct;9(10):e680-e689
pubmed: 36087612
Lancet HIV. 2017 Jan;4(1):e41-e50
pubmed: 27914874
Lancet HIV. 2020 Apr;7(4):e294-e300
pubmed: 32014116
BMC Public Health. 2020 Jan 15;20(1):69
pubmed: 31941469
AIDS Care. 2018 Nov;30(11):1435-1443
pubmed: 29701073
Nat Med. 2020 May;26(5):655-664
pubmed: 32405065
J Int AIDS Soc. 2020 Mar;23(3):e25463
pubmed: 32144874
AIDS. 2017 Jul 31;31(12):1755-1764
pubmed: 28590328
J Int AIDS Soc. 2017 Jul 25;20(1):21842
pubmed: 28741331
J Int AIDS Soc. 2020 May;23(5):e25491
pubmed: 32396700
Clin Infect Dis. 2020 Dec 3;71(9):e509-e512
pubmed: 32109293
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
BMC Public Health. 2014 Aug 14;14:843
pubmed: 25124267
Epidemics. 2022 Sep;40:100608
pubmed: 35843152
PLoS One. 2021 Oct 14;16(10):e0258542
pubmed: 34648589
J Int AIDS Soc. 2019 Apr;22(4):e25276
pubmed: 31037845
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
Ann Epidemiol. 2021 Jul;59:72-80
pubmed: 33930528
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
J Int AIDS Soc. 2022 Jan;25(1):e25861
pubmed: 35001515
PLoS Med. 2019 Sep 3;16(9):e1002885
pubmed: 31479452